FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Diplomat Pharmacy Chosen to Dispense Ocrevus to MS Patients Across US

























Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., has been selected to dispense Ocrevus (ocrelizumab), a limited-distribution drug, to people with relapsing  and primary progressive MS.

Ocrevus was approved by the U.S. Food and Drug Administration on March 28, becoming the first therapy approved for both RMS and PPMS — and the first therapy ever indicated as a primary progressive MS treatment. It was developed by Genentech, a member of the Roche Group, and is expected to be available by mid-April.

“We are excited to make this highly anticipated treatment option available to patients in need,” Paul Urick, Diplomat’s president, said in a press release. “Ocrevus can reduce the burden of MS and give patients hope.”

Ocrevus is a monoclonal antibody targeting B-cells (a type of immune cell) that express a protein called CD20 on their surface. CD20-positive B-cells are thought to directly cause damage to the myelin sheath — an insulating layer allowing signals to pass swiftly through neuronal extensions, known as axons. That damage initiates a series of immune reactions that debilitate MS patients.

Studies have shown that Ocrevus binds to B-cells with CD20 markers but not to stem cells or plasma cells, so as to preserve key immune functions.

A story about the development of Ocrevus and its mechanism of action can be found on this link. The treatment is given every six months by intravenous infusion.

Relapsing MS is the most common form of this disease, affecting around 85 percent of all patients. It is marked by flares, or relapses, defined as the appearance of new symptoms or the return of previous symptoms for 24 hours or more. Patients experience inflammatory attacks on nerve fibers and the myelin sheaths that protect them.

Up to 10% of people with MS are diagnosed with primary progressive MS, so named because it progresses from the onset of the first (primary) symptoms. PPMS symptoms steadily worsen over time without relapses or remissions.

MS is estimated to affect more than 2.3 million people worldwide, including about 400,000 people in the U.S.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News